Key clinical point: Maintenance therapy with an autologous tumor cell vaccine, gemogenovatucel-T, improved relapse-free survival among patients with advanced BRCA wild-type ovarian cancer.

Major finding: In patients with and without BRCA1/2 mutations, the median relapse-free survival was 12.6 months with gemogenovatucel-T and 8.4 months with placebo (P = .065). Among BRCA wild-type patients only, the median relapse-free survival was 19.4 months with the vaccine and 14.8 months with placebo (P = .007).

Study details: The phase 2 VITAL study included 91 patients with advanced ovarian cancer, 67 of whom had BRCA wild-type disease.

Disclosures: The trial is sponsored by Gradalis. Dr. Rocconi disclosed relationships with Gradalis, Genentech, Clovis, and Johnson & Johnson.